Experience

Karuna Therapeutics

• United States
• Biotechnology
• 100 - 200 Employee

• Staff Scientist, DMPK

  • Dec 2022 - Present



Cedilla Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientist I, DMPK

  • May 2022 - Nov 2022

  • Co-led a CDK2/Cyclin E lead optimization project which involved aligning cross-functional team members around project specific strategies to achieve stability and bioavailability DMPK goals for chemical matter in the “beyond rule of 5 space.” • Proven track record managing CROs including managing routine and custom ADME/PK studies through 4 external CROs in order to deliver time dependent results to meet quarterly DMPK goals. • Collaborated in a cross functional manner with biomolecular sciences and pharmacology to elucidate structure kinetics relationships in lead optimization to extend residence time of lead series from minutes to hours. Additionally, characterized pharmacodynamics with the effects of long residence time inhibitors in a disease relevant cell based assay.



Stony Brook University

• United States
• Higher Education
• 700 & Above Employee

• Researcher with Versatile Chemical Biology Experience in the Pharmaceutical Sciences

  • Aug 2017 - May 2022

  • Problem-solving skills with an ability to investigate, evaluate, and propose solutions for in vitro, cell-based, and ex vivo assay development leading to the successful completion of 3 projects funded by the NIH and the Stony Brook Renaissance School of Medicine.• Research and development experience with an ability to design CRISPR-Cas9 knock-in experiments as evidenced by findings in 2 research presentations.• Ability to work independently and within a team with strong proficiency and experience in assay development and troubleshooting as evidenced by the optimization of 4 methods in target engagement and pharmacodynamics.• Strong understanding of regulatory expectations with an ability to write, edit, and review internal technical reports relevant to IBC, IRB, and IACUC resulting in the completion of 9 technical documents.• Strong oral and written communications with an ability to write technical reports as demonstrated by obtaining 3 scientific grants ranging from $20,000 to $250,000 for progress on 2 projects studying target engagement biomarkers and targeted protein degradation.

• PK/PD Modeling Specialist

  • Aug 2017 - Dec 2021

  • Proven Track record in Pharmaceutical Sciences with experience in preclinical models, PK studies, ADME/DMPK, and CRO study management leading to successful completion of a study managed through a CRO to complete a PK/PD modeling project.• Technical Literacy with experience modeling and interpret pharmacokinetic data using GraphPad Prism, MATLAB, and Mathematica for 2 research projects• Ability to deepen technical understanding of software packages crucial for PK/PD modeling as evidenced by completion of 3 computational chemistry courses.

• Experienced Medicinal Chemist

  • Aug 2017 - Nov 2021

  - Proven track record in designing and executing multistep organic synthesis as evidenced by synthesizing a library of InhA inhibitors and assessing inhibition using enzymatic assays such as progress curves.- Experience in trouble-shooting organic synthesis challenges as evidenced by designing and synthesizing a library of 10 PROTACs to assess the phenotype of targeted degradation for a target in breast cancer to meet a project aim as part of a grant.



POET

• United States
• Biotechnology Research
• 700 & Above Employee

• Research Technician

  • Jan 2017 - May 2017

  ■ Built a company wide information management tool to track quality control KPIs related to ethanol production across POET’s 25 plants. ■ Wrote 3 standard operating procedures for new laboratory instrumentation which was rolled out to over 25 different company labs. ■ Developed professional awareness and adaptability working in 2 internships with POET which turned into a part-time position. ■ Built a company wide information management tool to track quality control KPIs related to ethanol production across POET’s 25 plants. ■ Wrote 3 standard operating procedures for new laboratory instrumentation which was rolled out to over 25 different company labs. ■ Developed professional awareness and adaptability working in 2 internships with POET which turned into a part-time position.



POET

• United States
• Biotechnology Research
• 700 & Above Employee

• Lignocellulosic Research Intern

  • May 2016 - Aug 2016



Antimicrobial Materials Incporporated

• Sioux Falls, South Dakota

• Research Associate

  • Nov 2015 - May 2016

  I worked for AMI as a research associate at the South Dakota Business Technology Center in conjunction with the University of South Dakota Biomedical Engineering Lab at the GEAR Center. I synthesized and characterized antimicrobial latex emulsion polymers. I worked to fulfill a quota of synthesized polymer for an industrial client for use in antimicrobial paints. During this synthesis, I modified the method and performed method development as the reaction was scaled up to 32.5X. During synthesis I was trained in acrylamide polymer synthesis, characterization using dynamic light scattering particle analysis. I also synthesized antimicrobial silica hybrid nanoparticles for incorporation into plastics with various potential antimicrobial uses particularly in the food processing industry. This quota of silica hybrid nanoparticles was to be used to fulfill a proof of concept for a phase II SBIR Grant. Working for a small start-up offers instruction at the intersection of the physical sciences and business. This opportunity also placed me in a position to be a part of the experimental design process, aid in problem solving, and learn directly from the CEO and Lead Senior Scientist.



POET

• United States
• Biotechnology Research
• 700 & Above Employee

• Quality Control Intern

  • May 2015 - Aug 2015



Augustana University (SD)

• United States
• Higher Education
• 300 - 400 Employee

• Undergraduate Research Assistant

  • May 2014 - Aug 2014

  Undergraduate Research Fellow in the Mays Lab. The research group is interested in exploiting the myrosinase/glucosinolate enzymatic processes as a means of achieving selective drug candidate activation. During my time in the Mays lab I performed a multistep organic synthesis of 2,2-diphenylethyl glucosinolate, a precursor whose breakdown product is a known p53 inhibitor. I also gained experience in small scale organic chemistry, chromatography methods, spectroscopic analysis, and experimental design.